Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related virusesRyo Shinnakasu, Tomohiro Kurosaki, Hiromi Yamamoto et al.|The Journal of Experimental Medicine|2021Cited by 34